Rhythm's IPO Exceeds Expections, Raises $120 Million In Debut Post author:Sam Post published:October 4, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like 5 Massachusetts Biotechs That Tanked More Than 60% in 2017 January 1, 2018 New York's Tyme Jumps as Pancreatic Cancer Drug Shines in Early-Stage Study January 18, 2018 AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017
AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017